Vaccine trials should seek to involve participants from the communities facing the highest risk of infection. With the rate Black and Latinx communities are disproportionately affected by COVID-19, current trials for the disease would need up to 40 percent of its participants to be Black or Latinx, a quota that is not being met.
Kathryn Stephenson, MD, and Bisola Ojikutu, MD, who both serve as directors of infectious disease research at Boston-based Beth Israel Deaconess Medical Center and Massachusetts General Hospital respectively, told STAT about the following steps researchers can take to ensure their trials accurately reflect the populations that the treatments in question will serve.
- Acknowledge the importance of racial diversity in clinical testing, even when trials may seem especially urgent.
- Give trial sites funding for diversity initiatives, since recruitment and logistics, such as transportation and translation, can add costs.
- Engage and communicate with Black and Latinx communities throughout the entire trial process, not just when it is time to report results.
- Show appreciation for people’s trust in the medical research community by creating treatments that keep them healthier and safer.
More articles on pharmacy:
CVS to open 200 more drive-thru COVID-19 testing sites
Cheap steroid in shortage after being posited as potential COVID-19 treatment
1 in 10 adults have a painkiller prescription, CDC finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.